Guangzhou Han
Chief Scientific Officer RadAlliance Therapeutics Inc
Guangzhou Han, MD, PhD, is Chief Scientific Officer at RadAlliance Therapeutics, where he leads the discovery and translational development of next-generation radiopharmaceutical diagnostics and therapeutics. He has over 15 years of oncology R&D experience, with deep expertise in radioligand therapy, PET imaging, target selection, translational strategy, and early clinical development. Dr. Han previously held leadership roles at Full-Life Technologies and RayzeBio, where he contributed to radiopharmaceutical pipeline strategy and program advancement, as well as oncology R&D roles at Peloton Therapeutics and Pfizer Oncology. His work is dedicated to developing differentiated radiopharmaceutical platforms and advancing novel targeted agents from discovery to clinical translation.
Seminars
- Discovering why radionuclide selection should be driven by target biology, tumour characteristics and pharmacokinetics rather than platform familiarity
- Examining how different isotopes may influence therapeutic index, dosimetry, manufacturability and ultimately clinical success across diverse target classes
- Sharing lessons from designing next-generation theranostic programmes where isotope selection is considered alongside target selection from the earliest stages
